Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-05-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司2023年度向特定对象发行A股股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a specific issuance of A shares to designated investors by 金宇生物技术股份有限公司 (Jinyu Bio-Technology Co., Ltd.) in 2023. It includes comprehensive information about the issuance background, purpose, pricing, share allocation, shareholder structure changes, regulatory approvals required, risk factors, and use of proceeds. The document is titled as a "2023年度向特定对象发行A股股票预案（修订稿）" which translates to "2023 Annual Plan for Private Placement of A Shares (Revised Draft)". This type of document is a formal proposal related to capital raising through share issuance to specific investors, which fits the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or other report types. The document length (15,000 characters) and detailed content confirm it is the actual proposal, not just an announcement of a report. Therefore, the correct classification is CAP with high confidence.
2023-05-09 Chinese
金宇生物技术股份有限公司关于2023年度向特定对象发行A股股票摊薄即期回报、填补回报措施及相关主体承诺（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific issuance of A shares to particular investors by the company 金宇生物技术股份有限公司. It discusses the dilution impact on immediate returns, financial assumptions, risk warnings, necessity and rationality of the issuance, use of raised funds, company reserves, governance measures, and commitments by directors and major shareholders to ensure the fulfillment of these measures. The document references regulatory guidelines and approvals from the China Securities Regulatory Commission (CSRC) and includes detailed financial impact analysis and corporate governance commitments. It is not a full annual or interim report, nor an earnings release or audit report. It is a detailed capital raising update with financial impact analysis and related commitments. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8031 characters) and content depth support this classification with high confidence.
2023-05-09 Chinese
金宇生物技术股份有限公司关于本次向特定对象发行股票不存在直接或通过利益相关方向参与认购的投资者提供财务资助或补偿的承诺
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company regarding a specific issuance of A shares to particular investors. It explicitly states that the company does not provide financial assistance or compensation to investors involved in the subscription. The document is brief (425 characters) and focuses on a capital issuance matter without detailed financial data or comprehensive reporting. This fits the category of a Capital/Financing Update (CAP) as it relates to the issuance of shares and clarifies financing arrangements. It is not a full report, regulatory filing, or other categories like director dealings or voting results.
2023-05-09 Chinese
金宇生物技术股份有限公司关于向特定对象发行A股股票预案（修订稿）披露的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement (573 characters) regarding the company's plan to issue A shares to specific investors. It references a detailed issuance plan disclosed on the stock exchange website but does not contain the full plan or financial data itself. The text explicitly states it is a "提示性公告" (a prompt or indicative announcement) about the issuance plan, not the issuance plan document itself. This fits the category of Capital/Financing Update (CAP), which covers updates on fundraising and capital structure changes. The document is not a full report, nor a regulatory filing or report publication announcement since it contains substantive information about the issuance plan approval process and risk notice. Therefore, the best classification is CAP with high confidence.
2023-05-09 Chinese
金宇生物技术股份有限公司关于公司控股股东、实际控制人拟变更的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from a listed company regarding a proposed change in its controlling shareholder and actual controller due to a planned private placement of shares to specific investors. It details the background of the involved parties, the shareholding structure before and after the issuance, and the associated risks. The document does not contain financial statements or detailed financial performance data but focuses on ownership and control changes. It is not a full financial report, earnings release, or management discussion. It is also not a proxy solicitation or voting results announcement. The content fits the category of a Capital/Financing Update (CAP) because it discusses a financing event (private placement) and its impact on control and shareholding structure. The document length is 3128 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is CAP with high confidence.
2023-05-09 Chinese
金宇生物技术股份有限公司2023年度向特定对象发行A股股票方案论证分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "2023 年度向特定对象发行 A 股股票 方案的论证分析报告" which translates to "2023 Annual Report on the Proposal for Private Placement of A Shares." It discusses the company's plan to issue A shares to specific investors, including the background, purpose, pricing, legal compliance, and impact on financial indicators. The content includes detailed financial analysis, legal references, shareholder structure, and strategic rationale for the capital raising. This is a comprehensive document related to a capital raising activity through private placement of shares, which fits the category of Capital/Financing Update (CAP). The document is lengthy (15,000 characters) and contains substantive financial and strategic information about the financing plan, not just an announcement or summary. Therefore, it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). It is not an Annual Report (10-K) or Interim Report (IR) as it focuses specifically on the capital raising plan. Hence, the correct classification is CAP with high confidence.
2023-05-09 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.